- Home
- GOSS vs SABA Comparison
GOSS vs SABA Comparison
Compare GOSS & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$11.53
Company Overview
Basic Information| Metric | GOSS | SABA |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 221.3M |
| IPO Year | 2018 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GOSS | SABA |
|---|---|---|
| Price | $11.53 | $8.00 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.19 | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 57.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $201.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $7.80 |
| 52 Week High | $12.52 | $9.18 |
Technical Indicators
Market Signals| Indicator | GOSS | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 81.80 | 40.09 |
| Support Level | $0.18 | $7.97 |
| Resistance Level | $12.52 | $8.40 |
| Average True Range (ATR) | 1.13 | 0.10 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 92.00 | 32.12 |
Price Performance
Historical Comparison GOSS
SABA
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.